Insider · SEC Form 4 filer
Ramiro Guerrero
Past buys: 1 of 4 beat
Companies
Where they file as an insider
MAIA Biotechnology (MAIA) Director Latest filing Sep 10, 2026
Track record
Did their buys beat the typical stock?
Open-market buys12
Quarters checked 6 months later4
Beat the typical stock 1 of 4
Quarters too new to check1
1 of 4 checked quarters beat the typical stock. A past record is data, not a forecast.
MAIA Biotechnology (MAIA) Bought Aug 20–Sep 10, 2026 · $252K · 185,078 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
MAIA Biotechnology (MAIA) Bought May 8, 2025 · $30K · 20,000 shares Behind typical Jun 30, 2025 $1.80 → Dec 31, 2025 $1.53 · −15.0% (typical stock +2.1%)
MAIA Biotechnology (MAIA) Bought Feb 24–Mar 3, 2025 · $160K · 106,666 shares Behind typical Mar 31, 2025 $1.53 → Sep 30, 2025 $1.54 · +0.7% (typical stock +7.3%)
MAIA Biotechnology (MAIA) Bought Nov 1–Dec 13, 2024 · $322K · 141,952 shares Behind typical Dec 31, 2024 $1.98 → Jun 30, 2025 $1.80 · −9.1% (typical stock −3.4%)
MAIA Biotechnology (MAIA) Bought Mar 14, 2024 · $8.11K · 6,928 shares Beat typical Mar 31, 2024 $2.20 → Sep 30, 2024 $2.81 · +27.7% (typical stock +3.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.